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Key Points
• STRATUS (MM-010), the
largest POM 1 LoDEX trial,
confirms the regimen offers
clinically meaningful benefit
and is generally well
tolerated.
• STRATUS supports POM 1
LoDEX as a standard of care
for patients with RRMM who
have poor prognosis and high
need for effective treatments.
Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor
prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus
low-dose dexamethasone in the largest cohort to date of patients with RRMM. Patients
who failed treatment with bortezomib and lenalidomide and had adequate prior
alkylator therapy were eligible. Pomalidomide 4 mg was given on days 1-21 of 28-day
cycleswith low-dose dexamethasone 40mg (20mg for patients aged >75 years) on days
1, 8, 15, and 22 until progressive disease or unacceptable toxicity. Safety was the
primary end point; secondary end points included overall response rate (ORR),
duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Among 682 patients enrolled, median age was 66 years, and median time since
diagnosis was 5.3 years. Median number of prior regimens was 5. Most patients were
refractory to both lenalidomide and bortezomib (80.2%). Median follow-up was 16.8
months; median duration of treatment was 4.9 months. Most frequent grade 3/4
treatment-emergent adverse events were hematologic (neutropenia [49.7%], anemia
[33.0%], and thrombocytopenia [24.1%]). Most common grade 3/4 nonhematologic
toxicitieswerepneumonia (10.9%) and fatigue (5.9%).Grade3/4 venous thromboembolismandperipheral neuropathywere rare (1.6%
each). TheORRwas 32.6%, and themedianDORwas 7.4months. MedianPFS andOSwere 4.6months and 11.9months, respectively.
Wepresent the largest trial todate evaluatingpomalidomideplus low-dosedexamethasone inpatientswithRRMM, further confirming
that this regimen offers clinically meaningful benefit and is generally well tolerated. www.Clinicaltrials.gov identifier NCT01712789.
(Blood. 2016;128(4):497-503)
Introduction
Patients with refractory or relapsed and refractory multiple myeloma
(RRMM) following treatment with newer agents (eg, lenalidomide and
bortezomib) have a poor prognosis characterized by a shortened overall
survival (OS).1 Thus, there is signiﬁcant unmet need for alternative
treatment options for this patient population. One such agent is
pomalidomide, a distinct IMiD immunomodulatory agent with
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tumoricidal and antiangiogenic activities.2 Preclinical studies of
pomalidomide have demonstrated antiproliferative and proapop-
totic activity in lenalidomide-resistant myeloma cells3-5 as well as
synergistic effects with dexamethasone.3,6
Two pivotal clinical studies of pomalidomide combined with
low-dose dexamethasone, MM-002 (phase 2) and MM-003
(phase 3), have demonstrated the clinical beneﬁt of this regimen
in patients with RRMM.7,8 In the randomized MM-002 study,
overall response rate (ORR; $ partial response [PR]) was sig-
niﬁcantly higher with pomalidomide plus low-dose dexametha-
sone comparedwith pomalidomide alone (33%vs 18%,P5 .013).7
Median progression-free survival (PFS) was also signiﬁcantly
greater in the pomalidomide plus low-dose dexamethasone group
(4.2 vs 2.7 months, P5 .003).7 The randomized phase 3 MM-003
study demonstrated that the combination of pomalidomide plus
low-dose dexamethasone led to signiﬁcant improvement in PFS
(4.0 vs 1.9 months, P , .0001) and OS (12.7 vs 8.1 months,
P 5 .0285) compared with high-dose dexamethasone,8 an OS
advantage that was conﬁrmed with longer follow-up despite 56%
of patients on the high-dose dexamethasone arm receiving sub-
sequent pomalidomide.9
Based on the results from MM-002 and MM-003, pomalidomide
was approved in the United States, the European Union, and other
countries around the world for the treatment of patients with RRMM
who have received $2 prior therapies (including lenalidomide and
bortezomib) and progressed on the last therapy (United States and
European Union), or within 60 days following completion of their last
therapy (United States).10,11
To further assess the safety and efﬁcacy of pomalidomide plus low-
dose dexamethasone, a phase 3b study, MM-010 (STRATUS), was
conducted in a large population of patients with RRMM. The results of
this study are presented in this paper.
Methods
Study design and participants
STRATUS (MM-010) is an open-label, single-arm phase 3b study undertaken at
91 centers in 19 countries across Europe. For inclusion in the study, patients had
to be at least 18 years of age, refractory to their last treatment, and have RRMM.
Patients had to have received$2 prior treatment lines, including$2 cycles of
lenalidomide and bortezomib (alone or in combination) and adequate prior
alkylator therapy ($4 cycles or progressive disease [PD] after $2 cycles or
received alkylator treatment as a part of a stem cell transplant). In addition, all
patients must have failed treatment with both bortezomib and lenalidomide,
deﬁned asPDonorwithin 60days of treatment (refractory), PD# 6months after
achieving a PR (relapsed), or intolerance to bortezomib.
Patients were ineligible if they had previously received therapy with
pomalidomide or had hypersensitivity to thalidomide, lenalidomide, or
dexamethasone. Peripheral neuropathy grade$ 2 or substantial cardiac disease
(NewYorkHeart Association class III or IV congestive heart failure,myocardial
infarction within 12 months prior to enrollment, or unstable or poorly controlled
angina pectoris) were exclusion criteria. Patients with the following laboratory
values were also considered ineligible: absolute neutrophil count ,800/mL;
platelets ,75 000/mL for patients in whom ,50% of bone marrow nucleated
cells were plasma cells or ,30 000/mL for patients in whom $50% of bone
marrownucleated cellswere plasma cells; creatinine clearance (CrCl),45mL/min
according to theCockcroft-Gault formulaor24-hoururinecollection12; hemoglobin
,8 g/dL; corrected serum calcium .3.5 mmol/L; total bilirubin .34.2 mmol/L;
or liver enzymes .3 times the upper limit of normal.
All patients providedwritten informed consent prior to the start of the study.
This study was approved by an institutional review board for each study site
prior to initiation of any studyprocedures andwasconducted in accordancewith
the Declaration of Helsinki and the principles of Good Clinical Practice (as
outlined by the International Conference on Harmonization E6 requirements).
Procedures
Patients were administered pomalidomide 4mg on days 1-21 of a 28-day cycle.
Patients also received low-dose dexamethasone 40 mg (if aged#75 years) or
20 mg (if aged.75 years) on days 1, 8, 15, and 22 of a 28-day cycle. Protocol
guidance for dose interruptions and reductions was similar to that used in the
MM-003 phase 3 study and are described elsewhere.8 Thromboprophylaxis
with low-dose aspirin, low-molecular-weight heparin, or equivalent was
required for all patients. Treatment was continued until PD or unacceptable
toxicity. Patients who discontinued treatment entered the follow-up phase,
where information on subsequent antimyeloma treatments, date of progression,
survival, and second primary malignancies (SPMs) were collected every 3
months for up to 5 years after enrollment of the last patient. Adverse events
(AEs) were recorded and graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, v. 4.0. Serious AEs were
those that resulted in death, were life-threatening, required hospitalization or
prolongation of hospitalization, caused a congenital anomaly or birth defect, or
constituted an important medical event.
Statistical analysis
The primary end point was safety as measured by the incidence of AEs (type,
frequency, severity, and relationship to study drugs), including SPMs. Key
secondary end points included pomalidomide exposure, ORR ($ PR) based on
the study investigator’s assessment and evaluated according to the International
Myeloma Working Group (IMWG) response criteria,13 duration of response
(DOR), PFS, OS, time to response, and time to progression. The safety
population was deﬁned as all patients who received$1 dose of trial treatment
and was used for all safety analyses. Efﬁcacy assessments were conducted in
the intention-to-treat (ITT) population (all enrolled patients). The trial was
designed to enroll patients for up to 24 months or until 720 patients were
enrolled, whichever came ﬁrst.
This study is registered with ClinicalTrials.gov (NCT01712789) and
EudraCT (2012-001888-78).
Table 1. Baseline characteristics
Characteristic ITT population (N 5 682)
Median age, y (range) 66 (37-88)
.65, n (%) 369 (54.1)
.70, n (%) 213 (31.2)
.75, n (%) 87 (12.8)
Sex, n (%)
Male 381 (55.9)
Female 301 (44.1)
Median time since initial diagnosis, y (range) 5.3 (0.6-28.2)
ECOG performance status, n (%)
0-1 614 (90.0)
2-3 68 (10.0)
ISS stage at study entry, n (%)
I-II 414 (60.7)
III 236 (34.6)
Missing 32 (4.7)
CrCl , 60 mL/min, n (%) 237 (34.8)
Median prior regimens, n (range) 5 (2-18)
.2 previous regimens, n (%) 637 (93.4)
Prior dexamethasone, n (%) 666 (97.7)
Prior lenalidomide, n (%) 682 (100.0)
Prior bortezomib, n (%) 682 (100.0)
Prior thalidomide, n (%) 372 (54.5)
Prior carfilzomib, n (%) 24 (3.5)
Prior stem cell transplant, n (%) 451 (66.1)
Lenalidomide refractory, n (%) 654 (95.9)
Bortezomib refractory, n (%) 571 (83.7)
Lenalidomide and bortezomib refractory, n (%) 547 (80.2)
ECOG, Eastern Cooperative Oncology Group; ISS, International Staging
System.
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Results
Patients
Between November 2012 and December 2014, the MM-010 study
enrolled 682 patients with RRMM, of whom 6 (0.9%) did not receive
study drug. With a median follow-up of 16.8 months as of the data
cutoff date of May 4, 2015, 104 patients (15.2%) remained on
treatment, and 572 patients (83.9%) have discontinued treatment.
The primary reason for treatment discontinuation was PD (62.2%),
followed by death (7.9%), AEs (5.9%), other causes (4.8%; including
clinical progressionwithout conﬁrmed IMWG-deﬁnedPDand transition
to commercial pomalidomide), withdrawal of consent (2.9%), and
lost to follow-up (,1.0%).
Themedian age of patients inMM-010was 66 years with a median
time from initial diagnosis of 5.3 years and a median of 5 (range, 2-18)
prior treatment regimens.Most patientswere refractory to lenalidomide
and/or bortezomib: 95.9% of patients were refractory to lenalidomide
and 4.1% were relapsed; 83.7% were refractory to bortezomib, 12.0%
were relapsed, and 4.3% were intolerant; and 80.2% of patients
were refractory to both lenalidomide and bortezomib. International
StagingSystemStage IIIwas reported for 34.6%of patients, 34.8%had
CrCl, 60mL/min, and 10.7% of patients had extramedullary disease.
Few patients had moderate cytopenia at baseline; 2.9% had grade 3
neutropenia and 11.0% had grade 3/4 thrombocytopenia. Additional
baseline characteristics are presented in Table 1.
Pomalidomide dosing and modification
The median treatment duration was 4.9 months with a median relative
dose intensity of 0.901, indicating that treatment was generally well
tolerated with a low-dose reduction/interruption rate and high treat-
ment compliance (Table 2). Dose reductions and interruptions of
pomalidomide due to AEs occurred in 22.0% and 66.3% of patients,
respectively. The most frequent AEs leading to dose reductions of
pomalidomide were neutropenia (5.9%), thrombocytopenia (4.3%),
fatigue (2.5%), and pneumonia (2.4%). AEs leading to dose
interruptions of pomalidomide were most commonly neutropenia
(22.6%), thrombocytopenia (11.1%), and pneumonia (10.2%).
Safety
Among the 676 treated patients, the most frequently reported grade 3/4
hematologic AEs were neutropenia (49.7%), anemia (33.0%), and
thrombocytopenia (24.1%; Table 3). The incidence of grade 3/4 febrile
neutropenia was 5.3%. Infections were the most frequent grade 3/4
nonhematologicAEs (28.1%, including 10.9%of patientswith grade 3/4
pneumonia). Results were similar regardless of age. In a subanalysis in
patients by age (#65 vs .65 years and #70 vs .70 years), the most
frequent grade 3/4 treatment-emergent AEs (TEAEs) across age groups
were neutropenia (47% to 51%), anemia (32% to 34%), thrombocyto-
penia (19%to26%), and infections (31%to37%).Overall, pneumoniaof
any grade occurred in 111 patients (16.4%). The majority of pneumonia
events resolved, with 13 patients (1.9%) having a fatal grade 5 event.
There was only one case of noninfectious pneumonitis. Occurrence of
neutropenia did not seem to affect the incidence of infections because
over half of infections (any grade) occurred in the absence of neutropenia
(57.2%). The rate of pomalidomide discontinuation due to infection
(1.6%)was low.Granulocytecolony-stimulating factorwasadministered
for 56.4% of patients with infections and 75.4% of patients with
neutropenia.Anti-infectiveswere used in 95.5%of patients experiencing
infections.Redbloodcell transfusions andplatelet transfusionswereused
in 48.4% and 16.1% of the entire patient population, respectively. Deep
vein thrombosis and pulmonary embolismwere infrequent with 1.6% of
patients experiencing grade 3/4 and 3.1% of patients experiencing a
venous thromboembolic event of any grade (Table 4). Fewer than 2% of
patients had grade 3/4 peripheral neuropathy (PN). PN of any grade was
experienced by 17.9% of patients, 43.8% of whom had PN at baseline,
and the median time to PN onset of any grade was 1.7 months.
Serious AEs were observed in 425 patients (62.9%). SPMs were
reported in 15 patients (5 patients had invasive solid tumors, and 10
patients had noninvasive skin cancers). The incidence rate of
developing an invasive solid tumor SPM was 0.90 per 100 person-
years (95% conﬁdence interval [CI]: 0.37, 2.16). The median time to
onset of the 5 solid tumor SPMs was 12.5 months (range, 5.9-20.6
months). Two of the solid tumor SPMs (squamous cell carcinoma of
Table 2. Pomalidomide dosing and most common causes of dose
modification
Safety population (N 5 676)
Median pomalidomide treatment duration,
mo (range)
4.9 (0.1-28.3)
Median pomalidomide relative dose intensity* 0.901
Overall discontinuation of pomalidomide due
to AE, n (%)
40 (5.9)
Due to thrombocytopenia 5 (0.7)
Due to pneumonia 4 (0.6)
Dose reduction of pomalidomide due to AE,
n (%)
149 (22.0)
Due to neutropenia 40 (5.9)
Due to thrombocytopenia 29 (4.3)
Due to fatigue 17 (2.5)
Due to pneumonia 16 (2.4)
Dose interruption of pomalidomide due to AE,
n (%)
448 (66.3)
Due to neutropenia 153 (22.6)
Due to thrombocytopenia 75 (11.1)
Due to pneumonia 69 (10.2)
*Relative dose intensity, dose intensity/planned dose intensity.
Table 3. Most commonly reported TEAEs (occurring in >10% [any
grade] of the safety population)
Safety population (N 5 676)
AE, n (%) Total Grade 3* Grade 4* Grade 5*
Neutropenia 383 (56.7) 200 (29.6) 136 (20.1) 0
Anemia 326 (48.2) 215 (31.8) 8 (1.2) 0
Thrombocytopenia 234 (34.6) 82 (12.1) 81 (12.0) 0
Fatigue 194 (28.7) 38 (5.6) 2 (0.3) 0
Pyrexia† 194 (28.7) 19 (2.8) 1 (0.1) 0
Constipation 155 (22.9) 5 (0.7) 0 0
Asthenia 153 (22.6) 20 (3.0) 3 (0.4) 0
Cough 133 (19.7) 2 (0.3) 0 0
Diarrhea 113 (16.7) 6 (0.9) 0 0
Dyspnea 113 (16.7) 18 (2.7) 2 (0.3) 1 (0.1)
Pneumonia 111 (16.4) 64 (9.5) 10 (1.5) 13 (1.9)
Peripheral edema 106 (15.7) 8 (1.2) 0 0
Back pain 98 (14.5) 15 (2.2) 1 (0.1) 1 (0.1)
Leukopenia 93 (13.8) 37 (5.5) 17 (2.5) 0
Muscle spasms 92 (13.6) 2 (0.3) 0 0
Nausea 92 (13.6) 2 (0.3) 0 0
Peripheral sensory neuropathy 73 (10.8) 4 (0.6) 1 (0.1) 0
Decreased appetite† 69 (10.2) 5 (0.7) 0 0
Insomnia 69 (10.2) 5 (0.7) 0 0
*Patients who experienced a particular event in more than one grade were
counted only once in the highest grade.
†One patient experienced a TEAE of unknown grade.
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the tongue and gastrointestinal stromal tumor) were diagnosed less
than a year following the start of study therapy. As of the data cutoff,
57.7% of the patients in the safety population had died. Of these,
68.5%ofdeaths (267/390 total safetypopulationdeaths) occurred after
treatment discontinuation (during follow-up). The most common
cause of death in the safety population was progression of multiple
myeloma (plasma cell myeloma [35.2%] and plasma cell leukemia
[0.4%]), followed by infections and infestations (9.3%), and general
disorders (5.6%).Deaths due toother causeswere infrequent. Infection
was also the most common cause of hospitalization (237 of the 390
patients hospitalized [60.8%]). Six percent of patients had TEAEs
leading to discontinuation of pomalidomide; thrombocytopenia
(0.7%) and pneumonia (0.6%) were the most frequent TEAEs leading
to pomalidomide discontinuation. Other TEAEs leading to discontin-
uation of pomalidomide included lung infection, general physical
health deterioration, pyrexia, dyspnea, cardiac failure, confusional
state, and renal failure (0.3% of patients for each).
Efficacy ORR
In the ITT population, the ORR was 32.6% (95% CI: 29.0, 36.2) with
7.6% of patients achieving a very good partial response and 0.6% of
patients achieving a complete response (Figure 1). The median time to
response was 1.9 months (range, 0.5-17.5 months), and the median
DOR was 7.4 months (95% CI: 6.5, 8.7). Results were similar for
patients refractory to lenalidomide, refractory to bortezomib, and
refractory to both lenalidomide and bortezomib with ORRs of 32.1%,
32.9%, and 32.4%, respectively. Stable diseasewas observed in 49.7%
(339/682) of patients. The median time to progression was 4.7 months
(95% CI: 4.2, 5.6).
ORR resultswere also similar for patientswith#3 vs.3 prior lines
of therapy (28.5% [95%CI: 22.1, 35.6] vs 34.1% [95%CI: 29.9, 38.4])
and in patients with (CrCl, 60 mL/min) or without renal impairment
(CrCl $ 60 mL/min) at study entry (30.8% [95% CI: 25.0, 37.1] vs
33.9% [95% CI: 29.4, 38.5]).
PFS
Median PFS was 4.6 months (95% CI: 3.9, 4.9) in the ITT population
(Figure 2A). Similar results were obtained in patients refractory to
lenalidomide (median PFS, 4.6 months [95% CI: 3.8, 4.9]), patients
refractory to bortezomib (median PFS, 4.2 months [95%CI: 3.8, 4.8]),
and patients refractory to both lenalidomide and bortezomib (median
PFS, 4.2 months [95% CI: 3.8, 4.7]). Median PFS was also similar
regardless of number of prior lines of therapy (#3 prior lines, 3.9
months [95% CI: 3.7, 5.1] vs.3 prior lines, 4.6 months [95% CI: 4.0,
5.3]) and in patientswith orwithoutmoderate renal impairment at study
entry (3.8 months [95% CI: 2.9, 4.6] vs 4.7 months [95%CI: 4.2, 5.6],
respectively).
OS
In the ITT population, median OS was 11.9 months (95% CI: 10.6,
13.4; Figure 2B). The median OS was similar regardless of prior
refractory statuswithmedianOSof11.9months (95%CI: 10.6, 13.4) in
patients refractory to lenalidomide, bortezomib, and both lenali-
domide and bortezomib. Similar results were also found regardless
of number of prior lines of therapy and moderate renal impairment
at study entry. Median OS was 12.8 (95% CI: 8.9, 18.4) vs 11.9
months (95%CI: 10.6, 13.0) for patients with#3 vs.3 prior lines,
respectively, and 10.2 (95%CI: 8.5, 12.0) vs 13.0 months (95%CI:
11.4, 14.7) in patients with or without moderate renal impairment,
respectively.
Table 4. AEs of interest
AE Safety population (N 5 676)
Any grade, n (%)
VTE* 21 (3.1)
Peripheral neuropathy† 121 (17.9)
Grade 3/4 AEs, n (%)
VTE* 11 (1.6)
Peripheral neuropathy† 11 (1.6)
*Includes the preferred terms, deep vein thrombosis and pulmonary embolism.
†Includes the preferred terms, neuropathy peripheral, peripheral sensory
neuropathy, paresthesia, hypoesthesia, polyneuropathy, peripheral sensorimotor
neuropathy, peripheral motor neuropathy, dysesthesia, gait disturbance, neuralgia,
amyotrophy, burning sensation, motor dysfunction, muscle atrophy, sensory
disturbance, and toxic neuropathy.
VTE, venous thromboembolic event.
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Figure 1. Investigator-assessed response to treatment
using IMWG criteria. BORT, bortezomib; CR, complete
response; LEN, lenalidomide; VGPR, very good partial
response.
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Discussion
The STRATUS study is the largest study conducted to date with
pomalidomide plus low-dose dexamethasone in a heavily pretreated
RRMMpatient population.All patients had previously been exposed to
both lenalidomide and bortezomib and received a median of 5 prior
antimyeloma treatment regimens. Pomalidomide plus low-dose
dexamethasonewas generally well tolerated. The safety proﬁle was
consistent with the proﬁle observed in the pivotal studies of
pomalidomide plus low-dose dexamethasone, and no new safety
signals were identiﬁed in this large patient population.7,8 Similar to
the MM-002 and MM-003 studies, the most frequent grade 3/4 AEs
were hematologic with a low incidence of febrile neutropenia;
discontinuations due to AEs were infrequent. Across all 3 studies,
neutropeniawas themost frequently observed grade 3/4 hematologic
AE occurring in 41.1%, 47.7%, and 49.7% of patients enrolled in
MM-002, MM-003, and the present study, respectively.7,8 The
incidence of grade 3/4 pneumonia (10.9%) observed in the present
study was similar to that observed in a prior pivotal phase 3 study of
pomalidomide plus low-dose dexamethasone (12.7%).8 The hema-
tologic and nonhematologic AEs tended to occur mostly in the early
cycles with a diminished frequency afterward (data not shown).
Dose interruptions and reductions with pomalidomide due to AEs
were 66.3% and 22.0%, respectively, and occurred most often as a
result of neutropenia or thrombocytopenia. However, the median
relative dose intensity remained high at 0.901, indicating that most
patients received close to the full dose of pomalidomide throughout
the study.
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Figure 2. Survival. (A) PFS. (B) OS.
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The efﬁcacy results observed with pomalidomide plus low-dose
dexamethasone in this study conﬁrm the clinical beneﬁt (ORR, PFS,
and OS) observed in other clinical trials. The ORR was 32.6%
(with 7.6% of patients achieving $ very good partial re-
sponse), which was similar to that observed in the MM-002
(ORR 5 32.7%), MM-003 (31.4%), and IFM-2009-02 (34.8%)
studies.7,8,14 The median DOR observed in this study (7.4
months) was consistent with that observed in the MM-002 (8.3
months), MM-003 (7.0 months), and IFM-2009-02 (6.4 months)
studies.7,8,14 The observed PFS and OS of 4.6 months and 11.9
months, respectively, were similar to the outcomes observed in
the MM-002 and MM-003 pivotal studies.7,8 In addition to the
efﬁcacy outcomes observed in the ITT population, ORR, PFS,
and OS were similar regardless of prior treatments, including
patients refractory to lenalidomide, bortezomib, or both lenalido-
mide and bortezomib, number of prior therapies, and presence or
absence ofmoderate renal impairment.The results of our studycompare
favorably with those from a study of daratumumab monotherapy in a
heavily pretreated population refractory to both lenalidomide and
bortezomib.15
The .7-month difference between PFS and OS may be
reﬂective of early identiﬁcation of biochemical relapse (which
precedes clinical manifestations of relapse) and subsequent salvage
regimens. Thus, despite being a heavily pretreated population,
patients who progress following treatment in this study may be
medically ﬁt enough to tolerate additional treatments. Indeed, the
pomalidomide and low-dose dexamethasone regimenhas been shown
to improve and prolong health-related quality of life vs high-dose
dexamethasone in the MM-003 study,16,17 which may make it
possible for patients to tolerate subsequent treatments that might not
otherwise have been an option.
This study conﬁrms previous analyses demonstrating that the
combination of pomalidomide and low-dose dexamethasone is a
safe and effective treatment of patients with RRMM who have
exhausted currently available treatment options. In addition,
patients who were refractory to lenalidomide and/or bortezomib
experienced similar clinical beneﬁts, supporting the sequential use
of these treatment regimens. Taken together, these data support
pomalidomide plus low-dose dexamethasone as a standard of care for
patients with RRMM who have poor prognosis and high need for
effective treatments.
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